secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001104659-22-058351
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Q1 net loss $11.6M; CF award up to $15.9M; cash into Q2 2023
------------------------------------------------------------------

- Net loss $11.6M ($0.13/sh) vs $8.7M ($0.22/sh) in Q1 2021; R&D $7.9M, G&A $3.1M.
- CF Foundation award up to $15.9M for ELX-02; Phase 2 CF topline results expected end H1 2022.
- Expanded ELX-02 development to Alport syndrome; Phase 2 proof-of-concept trial for nonsense mutations starts H2 2022.
- Cash $39.8M sufficient into Q2 2023; ZKN-013 IND for RDEB planned H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465922058351/0001104659-22-058351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465922058351/tm2215074d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-058351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer